These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37899394)

  • 1. Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair.
    Ge F; Liu X; Zhang H; Yuan T; Zhu H; Yang B; He Q
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):533-543. PubMed ID: 37899394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.
    Yuan T; Zeng C; Liu J; Zhao C; Ge F; Li Y; Qian M; Du J; Wang W; Li Y; Liu Y; Dai X; Zhou J; Chen X; Ma S; Zhu H; He Q; Yang B
    Signal Transduct Target Ther; 2024 Jan; 9(1):11. PubMed ID: 38177135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation.
    Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
    Cell Biol Int; 2022 Jul; 46(7):1089-1097. PubMed ID: 35568970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
    Ding X; Gu Y; Jin M; Guo X; Xue S; Tan C; Huang J; Yang W; Xue M; Zhou Q; Wang W; Zhang Y
    Theranostics; 2020; 10(13):6048-6060. PubMed ID: 32483437
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
    Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth.
    Zhang L; Xu B; Qiang Y; Huang H; Wang C; Li D; Qian J
    J Cell Mol Med; 2015 Apr; 19(4):799-805. PubMed ID: 25656529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer.
    Li J; Cheng D; Zhu M; Yu H; Pan Z; Liu L; Geng Q; Pan H; Yan M; Yao M
    Theranostics; 2019; 9(1):179-195. PubMed ID: 30662561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.
    Zhao M; Li X; Chen X
    J Bioenerg Biomembr; 2021 Apr; 53(2):177-189. PubMed ID: 33538941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway.
    Guo K; Ma Z; Zhang Y; Han L; Shao C; Feng Y; Gao F; Di S; Zhang Z; Zhang J; Tabbò F; Ekman S; Suda K; Cappuzzo F; Han J; Li X; Yan X
    J Exp Clin Cancer Res; 2022 Mar; 41(1):91. PubMed ID: 35277183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
    Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
    J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The deubiquitinase OTUD1 inhibits non-small cell lung cancer progression by deubiquitinating and stabilizing KLF4.
    Ma X; Wang L; Shi G; Sun S
    Thorac Cancer; 2022 Mar; 13(5):761-770. PubMed ID: 35098684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Significance of Immune Cell Infiltration and Prognosis of Non-Small-Cell Lung Cancer by Bioinformatics.
    Sun H; Sui B; Li Y; Yan J; Cao M; Zhang L; Liu S
    J Healthc Eng; 2021; 2021():3284186. PubMed ID: 34603645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of PSAT1 is Correlated with Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.
    Li H; Wu C; Chang W; Zhong L; Gao W; Zeng M; Wen Z; Mai S; Chen Y
    Front Biosci (Landmark Ed); 2023 Oct; 28(10):243. PubMed ID: 37919070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.
    Gu W; Zhuang W; Zhuang M; He M; Li Z
    Diagn Pathol; 2023 Nov; 18(1):119. PubMed ID: 37924135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
    Tessari A; Parbhoo K; Pawlikowski M; Fassan M; Rulli E; Foray C; Fabbri A; Embrione V; Ganzinelli M; Capece M; Campbell MJ; Broggini M; La Perle K; Farina G; Cole S; Marabese M; Hernandez M; Amann JM; Pruneri G; Carbone DP; Garassino MC; Croce CM; Palmieri D; Coppola V
    Oncogene; 2018 Dec; 37(50):6463-6476. PubMed ID: 30076413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
    Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
    Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
    Leung AW; Dragowska WH; Ricaurte D; Kwok B; Mathew V; Roosendaal J; Ahluwalia A; Warburton C; Laskin JJ; Stirling PC; Qadir MA; Bally MB
    Oncotarget; 2015 Jul; 6(19):17161-77. PubMed ID: 26220590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis.
    Seki T; Gong L; Williams AJ; Sakai N; Todi SV; Paulson HL
    J Biol Chem; 2013 Jun; 288(24):17145-55. PubMed ID: 23625928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.